Pushkal Garg Sells 1,548 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,548 shares of the firm’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the sale, the chief marketing officer now directly owns 11,989 shares of the company’s stock, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Friday, February 14th, Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $255.17, for a total transaction of $398,320.37.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $250.51 on Thursday. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The company has a 50-day moving average of $253.89 and a two-hundred day moving average of $263.20. The stock has a market cap of $32.43 billion, a price-to-earnings ratio of -115.44 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.94 earnings per share for the current year.

Wall Street Analyst Weigh In

ALNY has been the topic of a number of research analyst reports. Wolfe Research downgraded shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Barclays raised their price target on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. Scotiabank lowered their target price on shares of Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research note on Friday, February 14th. Piper Sandler reissued an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research note on Monday, November 18th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $299.48.

Institutional Trading of Alnylam Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $61,160,000. Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $41,529,000. Los Angeles Capital Management LLC lifted its stake in Alnylam Pharmaceuticals by 11,433.4% in the third quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after acquiring an additional 135,829 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Alnylam Pharmaceuticals by 13.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after acquiring an additional 2,285 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. lifted its stake in Alnylam Pharmaceuticals by 3.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after acquiring an additional 8,462 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.